

Capital Markets Day

29 October 2020

Copenhagen (& virtual), Denmark

A black and white photograph of a middle-aged man and a woman standing side-by-side, smiling and looking at each other. The man is on the left, wearing a dark sweater, and the woman is on the right, wearing a dark blazer and glasses.

We are the bigger picture

Patients have given consent to provide images

Speakers



Rachel Curtis
Moderator



Sören Tulstrup
CEO & President



Donato Spota
SVP & CFO



Christian Kjellman
SVP & CSO & COO



Vincenza Nigro
VP, Head of Medical Affairs



Prof. Nizam Mamode, M.D.
Professor of Transplant Surgery, Guy's and St Thomas' Hospital, London



Henk D. van Troostwijk
SVP & CCO



Achim Kaufhold
SVP & CMO



Prof. Mårten Segelmark
Professor of Nephrology at Lund University and Linköping University



Elisabeth Sonesson
Director & Head of Clinical Development



Emanuel Björne
VP & Head of Business Development



Lena Winstedt
Head of Science

Agenda

Hansa Biopharma Capital Markets Day 2020

Time	Length (min)	Topic	Presenter
13:30 – 13:35	00:05	Introduction	Klaus Sindahl, Head of IR and Rachel Curtis, Moderator
13:35 – 13:55	00:20	Our strategy and vision for the future	Søren Tulstrup, President and CEO
13:55 – 14:05	00:10	Our financial priorities	Donato Spota, SVP and CFO
14:05 – 14:30	00:25	Our scientific vision	Christian Kjellman, SVP CSO and COO
14:30 – 14:40	00:10	Break	
14:40 – 14:45	00:05	“Melissa” a patient’s perspective on the long wait for a kidney	Patient video
14:45 – 15:00	00:15	Building awareness around a new transformative therapy	Vincenza Nigro, VP and Head of Medical Affairs
15:00 – 15:30	00:30	Clinical perspectives on desensitization in kidney transplantation	Prof. Nizam Mamode, M.D. Clinician, Guy’s and St Thomas Hospital
15:30 – 15:50	00:20	Our European launch strategy	Henk Doude van Troostwijk, SVP and CCO
15:50 – 16:00	00:10	Break	
16:00 – 16:20	00:20	Opportunities beyond kidney transplantation	Prof. Achim Kaufhold, M.D. SVP and CMO
16:20 – 16:40	00:20	Anti-GBM disease and phase 2 data read-out	Prof. Mårten Segelmark M.D. Lunds & Linköpings University Elisabeth Sonesson, Director and Head of Clinical Operations
16:40 – 17:00	00:20	Imlifidase in gene therapy	Emanuel Björne, VP and Head of Business Development Lena Winstedt Head of Science
17:00 – 17:15	00:15	Questions from the audience	Rachel Curtis, Moderator
17:15 – 17:20	00:05	Closing remarks	Søren Tulstrup, President and CEO